An observational study in Malignant Female Reproductive System Neoplasm, Gynecologic Cancer and Gynecologic Neoplasm, sponsored by University of California, San Francisco. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by University of California, San Francisco · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Genital Neoplasms, Female with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Genital Neoplasms, Female · United States.
Among the 37 studies in Genital Neoplasms, Female with a site in United States, this one is one of 3 that started in 2023, is one of 4 observational ones, and was the 32nd registered.
81 studies on the registry are indexed under Genital Neoplasms, Female; 18 are open to participants now.
Browse Genital Neoplasms, Female studies →6 of the 37 studies in Genital Neoplasms, Female with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Women only
Corcept Therapeutics · Sites in United States, Belgium, France and 5 more countries
Ages 18+ · Women only
University of Utah · Sites in United States
Ages 18+ · Women only
Marengo Therapeutics, Inc. · Sites in United States, Canada, France and 1 more country
Ages 18+
UMC Utrecht · Sites in United States, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Genital Neoplasms, Female studies recruiting now, 8 (57%) set no upper age limit and 5 (36%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 10 · Phase 3 2
First in 1999; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 350 across 16 observational studies indexed under Genital Neoplasms, Female.
Median enrollment 40 across the 33 interventional studies, 750 across the 4 observational. Of the 24 that completed or were terminated, 13 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 37 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 1 study filed under Genital Neoplasms, Female — fewer than ten, so there is no comparison to draw.
6 of the studies in Genital Neoplasms, Female with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05979610University of UtahUsing Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies | 2026-12 |
| NCT06533059Alterome Therapeutics, Inc.A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | 2026-12-29 |
| NCT03141437M.D. Anderson Cancer CenterDecision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer | 2027-04-30 |
| NCT05592626Marengo Therapeutics, Inc.A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | 2027-09 |
| NCT05053230Memorial Sloan Kettering Cancer CenterA Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer | 2027-09-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 37 studies in Genital Neoplasms, Female with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.
PRIMARY OBJECTIVE:
I. Assess the risk factors associated with frailty in newly diagnosed gynecologic cancer participants.
SECONDARY OBJECTIVES:
I. Compare primary quality of life endpoint of "healthy days at home" between non-frail and frail participants (primary quality of life endpoint).
II. Compare other perioperative, oncologic, and quality of life outcomes between non-frail and frail participants.
OUTLINE: This is an observational study.
All new patients being evaluated for a new diagnosis of gynecologic cancer by the University of California, San Francisco (UCSF) Gynecologic Oncology service and the Dana-Farber Cancer Institute will be recruited in both the outpatient or inpatient setting. Study participants will be enrolled at the time of diagnosis and followed for up to one year after undergoing surgery for cancer.
Women undergoing evaluation for a newly diagnosed gynecologic malignancy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo physical function assessments, complete surveys, and medical records every 3 months +/- 4 weeks prior to standard of care surgery (outside of this protocol). After surgery subjects will be followed for at least 3 months +/- 4 weeks for up to one year after diagnosis. Medical record reviews will occur periodically to examine for long-term follow up oncologic outcomes of progression free survival, overall survival, and chemotherapy delays for up to 10 years after enrollment.
Other: Physical function assessment · Other: Self-reported Assessments and Questionnaires · Procedure: Surgery (Standard of Care, Non-Interventional)
Physical assessments of frailty will be conducted in person.
Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study
Also known as: Questionnaires
Surgical data will be reviewed via medical record
Also known as: Surgical Procedure
Proportion of participants who are categorized as frail
The Fried frailty phenotype (FP) assesses physical frailty through five criteria: unintentional weight loss; weakness or poor handgrip strength; self-reported exhaustion; slow walking speed; and low physical activity. Participants who receive a score of \>3 will be categorized as 'frail'. Participants who receive a score \<=3 will be categorized as Non-frail at time of enrollment.
Time frame: At time of enrollment, 1 day
Demographic risk factors associated with those who screen positive for frailty
Demographic risk factors obtained from medical record review (i.e. sex, age, race, ethnicity, cancer type, cancer histology, cancer stage, comorbidities, etc.) will be assessed and analyzed for differences between participants categorized as frail versus non-frail.
Time frame: At time of enrollment, 1 day
Oncologic risk factors associated with those who screen positive for frailty
Risk factors determined to be oncologic in nature will be assessed and analyzed for differences between participants categorized as frail versus non-frail.
Time frame: At time of enrollment, 1 day
Mean number of healthy days at home
The number of healthy days at home is defined as healthy days at home is defined as: 365 days minus (1) mortality days, (2) total number of days spent in inpatient, observation, skilled nursing facilities (SNF), rehabilitation, long-term hospital settings, emergency department and will be summarized and used as covariate in analysis.
Time frame: Up to 10 years
Mean length of hospital stay
The number of days participants stay in the hospital following standard of care surgery for gynecological cancer will be summarized and used as covariate in analysis.
Time frame: Up to 10 years
Percentage of participants readmitted to hospital
Participants with documented re-admission to a hospital following standard of care surgery for gynecological cancer will be summarized and used as a covariate in analysis.
Time frame: Up to 10 years
Percentage of participants with reported surgical complications
Participants with documented peri-operative complications following standard of care surgery for gynecological cancer will be summarized and used as a covariate in analysis.
Time frame: Up to 10 years
Mean time to initiation of standard of care chemotherapy
The median number of days following standard of care surgery for gynecological cancer to first standard of care chemotherapy initiation will be summarized and used as a covariate in analysis.
Time frame: Up to 10 years
Median Progression Free Survival (PFS)
Progression free survival is defined as the time from date of diagnosis to date of radiographic progression, and/or doubling of cancer antigen 125 (CA-125) from baseline.
Time frame: Up to 10 years
Median Overall Survival (OS)
Overall survival as defined by days from date of diagnosis to date of death, or study completion whichever occurs first.
Time frame: Up to 10 years
Mean number of treatment delays
Chemotherapy delays is defined by the number of chemotherapy infusions that are delayed due for medical purposes and the total number of days infusions are delayed for will be summarized and used as a covariate in analysis.
Time frame: Up to 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Nov 2027, 49 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →